LB Pharmaceuticals announced its first quarter 2026 financial results and progress on its lead drug candidate LB-102, which is in late-stage trials for schizophrenia and bipolar depression. The company initiated pivotal Phase 3 and Phase 2 trials, with topline data expected between late 2027 and mid-2029. A recent $100 million private placement boosts cash reserves to $365.6 million, funding operations through Q2 2029. LB-102 shows promise as a novel benzamide antipsychotic with potential to treat multiple neuropsychiatric disorders, including schizophrenia, bipolar depression, and major depressive disorder.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
